Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Senti Biosciences, Inc. - Common Stock (NQ:SNTI)

3.290 +0.240 (+7.87%)
Streaming Delayed Price Updated: 3:20 PM EDT, May 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Senti Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Why Is Faraday Future (FFIE) Stock Down 27% Today?
Faraday Future stock is down on Tuesday after the troubled EV company announced plans for a reverse split of FFIE shares. 
Via InvestorPlace
Why Is Senti Biosciences (SNTI) Stock Up 32% Today?
Senti Biosciences stock is up on Tuesday with heavy pre-market trading of SNTI shares despite a lack of news from the company. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Pre-market stock movers are worth checking out on Tuesday as we get into all of the hottest news worth reading about this morning! 
Via InvestorPlace
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
SNTI Stock Earnings: Senti Biosciences Reported Results for Q1 2024
Senti Biosciences just reported results for the first quarter of 2024. 
Via InvestorPlace
Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
From Senti Biosciences, Inc.
Via GlobeNewswire
Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights
From Senti Biosciences, Inc.
Via GlobeNewswire
Senti Bio Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML)
From Senti Biosciences, Inc.
Via GlobeNewswire
SNTI Stock Earnings: Senti Biosciences Misses EPS for Q4 2023
SNTI stock results show that Senti Biosciences missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights
From Senti Biosciences, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program
From Senti Biosciences, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why Is Blood Cancer Focused Senti Biosciences Stock Trading Higher Today?
Senti Biosciences Inc (NASDAQ: SNTI) received FDA clearance for its Investigational New Drug (IND) application for SENTI-202, an off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cell... 
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Senti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
From Senti Biosciences, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Checking out the biggest pre-market stock movers for Tuesday is the perfect way to get ready for another busy day of trading! 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time to start the day with a breakdown of the biggest pre-market stock movers worth keeping an eye on for Thursday! 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Senti Bio Announces Third Quarter 2023 Results and Pipeline Updates
From Senti Biosciences, Inc.
Via GlobeNewswire
Week In Review: Eccogen Out-Licenses GLP-1 Agonist To AstraZeneca In $2 Billion Deal
Eccogene, a Shanghai-Boston biotech, out-licensed global rights (ex-China) for its novel small molecule GLP-1 agonist to AstraZeneca in a $2 billion blockbuster deal. Eccogene will receive $185 million... 
Via Talk Markets
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Crude Oil Falls Sharply; Datadog Shares Spike Higher
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 1% on Tuesday The Dow traded up 0.21% to 34,166.89 while the NASDAQ rose 1.09% to 13,666.65. The S&P 500... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why Sanmina Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers PaxMedica, Inc. (NASDAQ: PXMD) shares climbed 173.8% to $8.35. PaxMedica announced the publication of its autism spectrum disorder Phase 2 study results in the Annals of General Psychiatry. 
Via Benzinga
Nasdaq Jumps 100 Points; US Trade Deficit Widens In September
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Tuesday The Dow traded up 0.19% to 34,159.14 while the NASDAQ rose 0.84% to 13,631.99. The... 
Via Benzinga
Topics Stocks
Exposures US Equities
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.